NCT02777229View on ClinicalTrials.gov

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

PHASE3CompletedINTERVENTIONAL

Enrollment

616

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2021

Conditions

HIV-1 Infection

Interventions

DRUG

Dolutegravir 50 mg

1 tablet once a day

DRUG

Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg

Fixed dose combination, 1 tablet once a day

DRUG

Efavirenz 400 mg

1 tablets once a day

Trial Locations (3)

Unknown

Cité verte Hospital, Yaoundé

Hopital Central, Yaoundé

Military Hospital, Yaoundé

All Listed Sponsors

collaborator

Institut de Recherche pour le Developpement

OTHER_GOV

collaborator

UNITAID

OTHER

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02777229 - Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings | Biotech Hunter | Biotech Hunter